【佳学基因靶向药物基因检测】奥希替尼对携带原发性EGFR-T790M突变的肺腺癌肺段切除术后对侧多发磨玻
2023-07-12 15:00阅读：
国内肿瘤检测指标机构排行榜加密
这的药物化治疗及药物选择听到《J Cardiothorac Surg》在 2022 Dec
19;17(1):324.发表了一篇题目为《Review》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Haijun Dong,
Jianbin Zhang, Weiwei Min, Qibin
Shen等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。
肿瘤基因检测及靶向药物治疗研究关键词：
表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKI),多发磨玻璃结节 (mGGNs),同步多原发性肺癌 (SMPLC)。
肿瘤治疗检测基因临床应用结果
靶向药物研究立项的依据：肺部多发磨玻璃结节（mGGNs）已被定义为同时性多原发性肺癌（SMPLC），SMPLC与肺内转移瘤的鉴别难度很大，其治疗仍存在争议。病例介绍：我们报道一例mGGNs与原发性EGFR-T790M突变肺腺癌同时发生，患者行左上肺病灶根治性切除，右肺各叶残留mGGNs继续奥希替尼治疗。这些
mGGNs 对奥希替尼表现出不同的反应。药物指导及病因判断的依据：我们报告了 mGGNs
术后治疗的成功策略。对于无法完全切除的，则进行了化疗、放疗、立体定向放疗、免疫治疗和靶向治疗。
EGFR-TKI治疗策略显示出显着优势，但如何达到更好的治疗效果还需要更多研究。关键词：表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）；多发磨玻璃结节
(mGGNs)；同步多原发性肺癌 (SMPLC)。
肿瘤发生与革命国际数据库描述：
Background: Multiple ground-glass nodules (mGGNs) in the
lung has been defined as synchronous multiple primary lung cancer
(SMPLC), it is has been very difficult challenging to differentia
te SMPLC from intrapulmonary metastases, and its treatment remains
controversial.Case presentation:
We report a case
simultaneously involving mGGNs and lung adenocarcinoma harboring
primary EGFR-T790M mutation, in which the patient underwent the
radical resection of lesions in the left upper lung, and continued
the osimertinib treatment for the residual mGGNs in all lobes of
the right lung. These mGGNs displayed different responses to
osimertinib.Conclusions:
We reported a successful strategy
on the postoperative treatment for mGGNs. For those that cannot be
completely resected, the chemotherapy, radiotherapy, stereotactic
body radiation therapy, immunotherapy and targeted therapy have
been performed instead. The EGFR-TKI therapy strategy showed
significant advantages, but how to achieve even better therapeutic
effect needs more researches.Keywords:
Epidermal growth
factor receptor-tyrosine kinase inhibitor (EGFR-TKI); Multiple
ground-glass nodules (mGGNs); Synchronous multiple primary lung
cancer (SMPLC).
